KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Gross Profit (2016 - 2025)

Historic Gross Profit for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $10.5 billion.

  • AbbVie's Gross Profit rose 218.58% to $10.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 billion, marking a year-over-year increase of 1145.47%. This contributed to the annual value of $39.4 billion for FY2024, which is 1630.24% up from last year.
  • Latest data reveals that AbbVie reported Gross Profit of $10.5 billion as of Q3 2025, which was up 218.58% from $11.1 billion recorded in Q2 2025.
  • AbbVie's 5-year Gross Profit high stood at $11.1 billion for Q2 2025, and its period low was $7.4 billion during Q3 2023.
  • Over the past 5 years, AbbVie's median Gross Profit value was $9.8 billion (recorded in 2022), while the average stood at $9.7 billion.
  • Its Gross Profit has fluctuated over the past 5 years, first soared by 4054.22% in 2021, then plummeted by 2398.37% in 2023.
  • Over the past 5 years, AbbVie's Gross Profit (Quarter) stood at $10.6 billion in 2021, then rose by 3.64% to $11.0 billion in 2022, then dropped by 21.5% to $8.6 billion in 2023, then grew by 24.53% to $10.7 billion in 2024, then decreased by 2.19% to $10.5 billion in 2025.
  • Its Gross Profit stands at $10.5 billion for Q3 2025, versus $11.1 billion for Q2 2025 and $9.3 billion for Q1 2025.